Successful Management of Lenvatinib-Induced Proteinuria and Hypertension with an Angiotensin Receptor-Neprilysin Inhibitor (ARNI) and Finerenone: A Case Report (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO1264; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "She had prior thyroidectomy for thyroid cancer and sequential TKI use (sorafenib, anlotinib) before lenvatinib, with no history of hypertension or diabetes...Sacubitril/valsartan 200 mg bid and furosemide were started...Discussion In lenvatinib-induced nephrotic-range proteinuria where drug cessation is not an option, dual blockade with sacubitril/valsartan and finerenone achieved sustained proteinuria reduction, enabling continued oncological therapy. The withdrawal-rechallenge observation provides compelling evidence for finerenone's role in this setting and warrants further investigation in onconephrology."
Case report • Clinical • Cardiovascular • Diabetes • Hypertension • Metabolic Disorders • Nephrology • Ovarian Cancer • Renal Disease • Solid Tumor • Thyroid Gland Carcinoma
|